Navigation Links
Study finds new genetic error in some lung cancers
Date:10/28/2013

BOSTON A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion a forced merger of two normally separate genes that spurs the cells to divide rapidly, scientists at Dana-Farber Cancer Institute and the University of Colorado Cancer Center report in a new paper in the journal Nature Medicine. Treating the cells with a compound that blocks a protein encoded by one of those genes NTRK1 caused the cells to die.

The finding suggests that the fusion of NTRK1 to other genes fuels the growth of some lung adenocarcinomas (a form of non-small cell lung cancer), and that drugs that target NTRK1's protein product could be effective in patients whose lung tumors harbor such fusions.

"Treatment with targeted therapies is now superior to standard chemotherapy for many patients with lung cancers that harbor genetic changes including those with fusions involving the gene ALK," says Pasi A. Jnne, MD, PhD, of Dana-Farber, the senior co-author of the paper with Robert C. Doebele, MD, PhD, of CU Cancer Center. "We know of several other genes that are fused in lung cancer and that offer attractive targets for new therapies. Our discovery places lung adenocarcinomas with NTRK1 fusions squarely within that group."

In the study, researchers performed next-generation DNA sequencing tests which read the individual elements of the genetic code over long stretches of chromosomes on tumor samples from 36 patients with lung adenocarcinomas whose tumors did not contain any previously known genetic alterations that could be found with standard clinical tests. In two of those samples both from women who had never smoked investigators found that a key region of the NTRK1 gene had become fused to normally distant genes (to the gene MPRIP in one patient; and the gene CD74 in the other).

NTRK1 holds the blueprint for a protein called TRKA, which dangles from the surface of cells and receives growth signals from other cells. The binding of NTRK1 to other genes causes TRKA to issue cell-growth orders on its own, without being prompted by outside signals.

In the laboratory, investigators mixed NTRK1-inhibiting agents into lung adenocarcinoma cells harboring NTRK1 fusions. The result was a dampening of TRKA's activity and the death of the cancer cells.

Investigators then designed a new test using fluorescence in situ hybridization (FISH) to detect NTRK1 fusions and tested an additional 56 tumor samples. In total, three of 91 tumor samples which had no other sign of cancer-causing genetic abnormalities, had fusions involving NTRK1.

"These findings suggest that in a few percent of lung adenocarcinoma patients people in whose cancer cells we had previously been able to find no genetic abnormality tumor growth is driven by a fusion involving NTRK1," Jnne says. "Given that lung cancer is a common cancer, even a few percent is significant and translates into a large number of patients. Our findings suggest that targeted therapies may be effective for this subset of lung cancer patients."

"This is still preclinical work," Doebele says, "but it's the first and maybe even second and third important steps toward picking off another subset of lung cancer with a treatment targeted to the disease's specific genetic weaknesses."


'/>"/>

Contact: Robbin Ray
robbin_ray@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. Exhaled breath biomarker may detect lung cancer, study presented at Chest 2013
2. Headaches in lupus patients not linked to disease activity study says
3. New study examines link between pregnancy weight gain, autism spectrum disorders
4. 11 new genetic susceptibility factors for AD discovered through the largest study
5. Young people report worse fibromyalgia than older patients, Mayo Clinic study shows
6. DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA
7. Multicenter Study Led by Texas Children's Hospital & Baylor College of Medicine Finds Prenatal Diagnosis & Birth Location May Significantly Improve Neonatal HLHS Survival
8. Antibiotic Resistance 2013: A Global Market Study
9. Study ties bone marrow transplant to negative sexual side effects
10. Preclinical study finds drug helps against pancreatic cancer
11. Mayo Clinic study: Uterine fibroids have significant impact on quality of life, workplace performance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study finds new genetic error in some lung cancers
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a provider of cloud-based ... Secure Messaging platform, which includes secure, private messaging, large file sharing, secure e-signatures, ... of patents around innovative features for securing, tracking, and controlling messages for organizations ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare ... today announced it has secured $9 million in Series A funding led by ... investment will be used by Somnoware to further fulfill its mission to connect, ...
(Date:5/4/2016)... Palm City, Florida (PRWEB) , ... May 04, ... ... providers of cold therapy products, announced today the introduction of the innovative newly ... for post operative hip replacement patients. The plush design enhances comfort and enables ...
(Date:5/4/2016)... ... 04, 2016 , ... a2z, Inc. is pleased to announce ... for Enterostomal Therapy (CAET) will be utilizing powerful and innovative technology solutions to ... exhibitors for the 2016 WOCN Society & CAET Joint Conference—which is the largest ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today ... central New Jersey residents. What started out as an idea to provide a ... integrated approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... 3, 2016 ACME Markets, ... and Delaware County Councilman Dave White ... in all ACME pharmacies across ... Control and Prevention (CDC), naloxone has saved 26,463 lives nationwide over ... Delaware County were authorized to administer naloxone ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology: